Relationship of serum N-acetyl-beta-glucosaminidase activity to oxidative stress in diabetes mellitus
Language English Country Netherlands Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
10340445
DOI
10.1016/s0009-8981(99)00025-x
PII: S0009-8981(99)00025-X
Knihovny.cz E-resources
- MeSH
- Acetylglucosaminidase blood MeSH
- Diabetes Mellitus blood enzymology MeSH
- Adult MeSH
- Body Mass Index MeSH
- Middle Aged MeSH
- Humans MeSH
- Malondialdehyde blood MeSH
- Oxidative Stress * MeSH
- Superoxide Dismutase blood MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Acetylglucosaminidase MeSH
- Malondialdehyde MeSH
- Superoxide Dismutase MeSH
Serum N-acetyl-beta-glucosaminidase activity was evaluated in 40 Type 1 and 40 Type 2 diabetic patients and compared with parameters of diabetes control and oxidative stress. Significantly increased mean serum N-acetyl-beta-glucosaminidase activity was found in both groups of diabetic patients as compared with the corresponding group of healthy persons (p < 0.01). Oxidative stress measured by plasma malondialdehyde concentration was significantly higher in Type 2 than in Type 1 diabetic patients (p < 0.01) but in comparison with control subjects it was higher only in Type 2 diabetes. Plasma malondialdehyde concentration positively correlated with body mass index (r=0.77, p<0.001) and with serum N-acetyl-beta-glucosaminidase activities (r=0.57, p <0.001). Treatment of 10 Type 2 diabetic patients with antioxidant alpha-tocopherol caused a significant decrease in malondialdehyde concentration (p < 0.001) which was accompanied by a decrease of N-acetyl-beta-glucosaminidase activity (p < 0.01). We conclude that serum N-acetyl-beta-glucosaminidase activity may be influenced by oxidative stress which is more pronounced in Type 2 than in Type 1 diabetic patients.
References provided by Crossref.org
Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus